Lyra Therapeutics, Inc.

Informe acción NasdaqGM:LYRA

Capitalización de mercado: US$12.4m

Lyra Therapeutics Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Maria Palasis

Chief Executive Officer (CEO)

US$1.8m

Compensación total

Porcentaje del salario del CEO32.7%
Permanencia del CEO9.8yrs
Participación del CEOn/a
Permanencia media de la dirección2.3yrs
Promedio de permanencia en la Junta Directiva4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Jul 05

Lyra Therapeutics: Progress In The Clinic

May 18

A First Look At Lyra Therapeutics

Apr 21

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Maria Palasis en comparación con los beneficios de Lyra Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$583k

-US$63m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$583k

-US$55m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$48m

Dec 31 2021US$2mUS$552k

-US$44m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$4mUS$471k

-US$22m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$843kUS$388k

-US$17m

Compensación vs. Mercado: La compensación total de Maria($USD1.79M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.07K).

Compensación vs. Ingresos: La compensación de Maria ha aumentado mientras la empresa no es rentable.

CEO

Maria Palasis (59 yo)

9.8yrs

Permanencia

US$1,785,375

Compensación

Dr. Maria Palasis, Ph D, serves as Director at PanTher Therapeutics, Inc. since June 2021. Dr. Palasis has been Chief Executive Officer, President and Director of Lyra Therapeutics, Inc. since January 2015...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 49.5k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79msin datos
Carmichael Roberts
Co-Founderno datasin datossin datos
Jason Cavalier
CFO, Treasurer & Secretary3.2yrsUS$1.07msin datos
Ray Knox
Vice President of Operationsno datasin datossin datos
Ronan O'Brien
Chief Legal Officer1.1yrssin datossin datos
Vineeta Belanger
Senior Vice President of Clinical Affairsno datasin datossin datos
Robert Richard
Senior Vice President of Technical Operations1.8yrsUS$666.79ksin datos
Robert Kern
Chief Clinical Advisor3.8yrssin datossin datos
Gloria Cosgrove
Senior Vice President of Quality1.8yrssin datossin datos
Allison Nance
Senior Vice President of Regulatory Affairs1.8yrssin datossin datos
Elazer Edelman
VP of Finance & Riskno datasin datossin datos

2.3yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LYRA se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 49.5k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79msin datos
James Tobin
Lead Independent Director2.7yrsUS$152.31k0%
$ 0
W. Smith
Independent Director5yrsUS$123.81k0%
$ 0
George Whitesides
Member of Scientific Advisory Board4.1yrsUS$333.93ksin datos
C. Merrifield
Independent Director5.2yrsUS$113.06k0.017%
$ 2.1k
Robert Langer
Member of Scientific Advisory Board4.1yrsUS$19.36ksin datos
Michael Dake
Member of Medical Advisory Boardno datasin datossin datos
William Gray
Member of Medical Advisory Boardno datasin datossin datos
Mahmood Razavi
Member of Medical Advisory Boardno datasin datossin datos
Gary Ansel
Member of Medical Advisory Boardno datasin datossin datos
I. Baumgartner
Member of Medical Advisory Boardno datasin datossin datos

4.1yrs

Permanencia media

73yo

Promedio de edad

Junta con experiencia: La junta directiva de LYRA se considera experimentada (4.1 años de antigüedad promedio).